ketoconazole has been researched along with Invasiveness, Neoplasm in 4 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fixed dosing was found to be feasible, without increased variability of clearance or neutrophil toxicity compared to BSA-based dosing." | 2.73 | A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers. ( Goh, BC; Lee, HS; Lee, SC; Soo, R; Sukri, N; Tham, LS; Wang, LZ; Wong, CI; Yong, WP, 2008) |
| "Invasion and metastasis are responsible for 90% of cancer-related mortality." | 1.42 | 4-Fluoro-3',4',5'-trimethoxychalcone as a new anti-invasive agent. From discovery to initial validation in an in vivo metastasis model. ( Bracke, ME; De Ryck, T; Katritzky, AR; Patronov, A; Roman, BI; Slavov, SH; Stevens, CV; Vanhoecke, BW, 2015) |
| "The case of a patient with recurrent esthesioneuroblastoma complicated by ectopic adrenocorticotropic hormone production is presented, including the workup and management of this uncommon complication of an uncommon disease." | 1.36 | Esthesioneuroblastoma (Olfactory Neuroblastoma) with Ectopic ACTH Syndrome: a multidisciplinary case presentation from the Joan Karnell cancer center of Pennsylvania Hospital. ( Benito, M; Mintzer, DM; Nagamine, M; Newman, J; Zheng, S, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Roman, BI | 1 |
| De Ryck, T | 1 |
| Patronov, A | 1 |
| Slavov, SH | 1 |
| Vanhoecke, BW | 1 |
| Katritzky, AR | 1 |
| Bracke, ME | 1 |
| Stevens, CV | 1 |
| Machiels, JP | 1 |
| Staddon, A | 1 |
| Herremans, C | 1 |
| Keung, C | 1 |
| Bernard, A | 1 |
| Phelps, C | 1 |
| Khokhar, NZ | 1 |
| Knoblauch, R | 1 |
| Parekh, TV | 1 |
| Dirix, L | 1 |
| Sharma, S | 1 |
| Mintzer, DM | 1 |
| Zheng, S | 1 |
| Nagamine, M | 1 |
| Newman, J | 1 |
| Benito, M | 1 |
| Yong, WP | 1 |
| Wang, LZ | 1 |
| Tham, LS | 1 |
| Wong, CI | 1 |
| Lee, SC | 1 |
| Soo, R | 1 |
| Sukri, N | 1 |
| Lee, HS | 1 |
| Goh, BC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label, Multicenter Study to Assess the Potential Effects of Ketoconazole on the Pharmacokinetics of Trabectedin in Subjects With Advanced Malignancies[NCT01267084] | Phase 1/Phase 2 | 12 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| An Open-Label, Multicenter Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Subjects With Advanced Malignancies[NCT01273480] | Phase 1 | 12 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for ketoconazole and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.
Topics: Adult; Antineoplastic Agents; Cytochrome P-450 CYP3A; Dioxoles; Dose-Response Relationship, Drug; Dr | 2014 |
Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.
Topics: Adult; Antineoplastic Agents; Cytochrome P-450 CYP3A; Dioxoles; Dose-Response Relationship, Drug; Dr | 2014 |
Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.
Topics: Adult; Antineoplastic Agents; Cytochrome P-450 CYP3A; Dioxoles; Dose-Response Relationship, Drug; Dr | 2014 |
Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.
Topics: Adult; Antineoplastic Agents; Cytochrome P-450 CYP3A; Dioxoles; Dose-Response Relationship, Drug; Dr | 2014 |
A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers.
Topics: Antineoplastic Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Docetaxel; Dose-R | 2008 |
2 other studies available for ketoconazole and Invasiveness, Neoplasm
| Article | Year |
|---|---|
4-Fluoro-3',4',5'-trimethoxychalcone as a new anti-invasive agent. From discovery to initial validation in an in vivo metastasis model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biological Products; Cell Line, Tumor; Cell Movement; Ce | 2015 |
Esthesioneuroblastoma (Olfactory Neuroblastoma) with Ectopic ACTH Syndrome: a multidisciplinary case presentation from the Joan Karnell cancer center of Pennsylvania Hospital.
Topics: ACTH Syndrome, Ectopic; Adrenocorticotropic Hormone; Anti-Inflammatory Agents; Antifungal Agents; An | 2010 |